Class Action Cases

Recro Pharma, Inc.

Join Class Action »

According to the Complaint, Recro Pharma made false and misleading statements to the marketplace. The Company’s lead product, IV meloxicam, was unlikely to receive FDA approval due to lacking sufficient supporting clinical data to demonstrate significant clinical benefits. As a result, Recro Pharma’s public statements were materially false and misleading throughout the class period and did not accurately reflect the results of business operations and the financial health of the Company. According to the lawsuit, when accurate information about the Company became apparent in the market, investors suffered damages.

Press Release

INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Recro Pharma, Inc. (”Recro Pharma” or ”the Company”) (NASDAQ: REPH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between July 31, 2017, and May 23, 2018, inclusive (the ”Class Period”), are encouraged to contact the firm before July 30, 2018.

If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, Recro Pharma made false and misleading statements to the marketplace. The Company’s lead product, IV meloxicam, was unlikely to receive FDA approval due to lacking sufficient supporting clinical data to demonstrate significant clinical benefits. As a result, Recro Pharma’s public statements were materially false and misleading throughout the class period and did not accurately reflect the results of business operations and the financial health of the Company. According to the lawsuit, when accurate information about the Company became apparent in the market, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
Sherin Mahdavian, Esq.,
www.schallfirm.com

SOURCE: The Schall Law Firm

 

Cases

  • Drop files here or
    Accepted file types: xls, xlsx, doc, pdf, jpg, jpeg.
    You may redact your account numbers from your uploaded documents. The Schall Law Firm is committed to protecting the privacy of confidential information. Your documents will be securely held in AWS S3 and will only be used as proof of your transactions in connection with this matter.
  • Purchases
    Date Format: MM slash DD slash YYYY
  • Sales
    Date Format: MM slash DD slash YYYY
  • By submitting your information, you acknowledge that this form does not create an attorney-client relationship between yourself and The Schall Law Firm. Any information you submit will be maintained as confidential. The Schall Law Firm, in its sole discretion, will contact you if it requires further information from you.